Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

DMTK

DermTech Inc

May 03 • 04:00PM ET

0.6290

Dollar change -0.0004
Percentage change -0.06	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC AVSC

Index	-	P/E	-	EPS (ttm)	-3.13	Insider Own	11.91%	Shs Outstand	34.52M	Perf Week	4.29%
Market Cap	21.78M	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-0.39%	Shs Float	30.50M	Perf Month	-3.08%
Income	-100.89M	PEG	-	EPS next Q	-0.57	Inst Own	16.27%	Short Float	10.11%	Perf Quarter	-48.86%
Sales	15.30M	P/S	1.42	EPS this Y	33.14%	Inst Trans	-24.29%	Short Ratio	10.58	Perf Half Y	-54.42%
Book/sh	1.66	P/B	0.38	EPS next Y	12.27%	ROA	-62.28%	Short Interest	3.08M	Perf Year	-78.53%
Cash/sh	1.61	P/C	0.39	EPS next 5Y	-	ROE	-106.46%	52W Range	0.57 - 3.90	Perf YTD	-64.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-93.00%	52W High	-83.87%	Beta	2.62
Dividend TTM	-	Quick Ratio	4.52	Sales past 5Y	40.82%	Gross Margin	1.80%	52W Low	9.97%	ATR (14)	0.05
Dividend Ex-Date	-	Current Ratio	4.59	EPS Y/Y TTM	19.38%	Oper. Margin	-678.21%	RSI (14)	44.97	Volatility	8.72% 7.62%
Employees	208	Debt/Eq	0.95	Sales Y/Y TTM	5.36%	Profit Margin	-659.57%	Recom	2.20	Target Price	2.28
Option/Short	Yes / Yes	LT Debt/Eq	0.90	EPS Q/Q	40.39%	Payout	-	Rel Volume	0.51	Prev Close	0.63
Sales Surprise	-2.86%	EPS Surprise	0.90%	Sales Q/Q	31.06%	Earnings	Feb 29 AMC	Avg Volume	291.50K	Price	0.63
SMA20	1.40%	SMA50	-15.58%	SMA200	-57.95%	Trades		Volume	147,623	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-18-22	Resumed	Oppenheimer	Outperform	$48
Jun-14-22	Reiterated	BTIG Research	Buy	$38 → $19
Jan-07-22	Initiated	Stephens	Overweight	$26
Oct-15-21	Resumed	Cowen	Outperform	$50
May-03-21	Initiated	BTIG Research	Buy	$53
Jan-22-21	Initiated	Oppenheimer	Outperform	$53
Dec-14-20	Initiated	Craig Hallum	Buy	$23
Oct-30-20	Initiated	William Blair	Outperform
Dec-05-19	Initiated	Lake Street	Buy

Apr-18-24 04:15PM	DermTech to Explore Strategic Alternatives and Implement Restructuring Plan (Business Wire)
Apr-01-24 04:05PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-08-24 08:05AM	DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology (Business Wire)
Feb-29-24 04:01PM	DermTech Reports Fourth-Quarter 2023 Financial Results (Business Wire)
Feb-13-24 08:05AM	DermTech Announces Release Date for Fourth-quarter 2023 Financial Results (Business Wire)
04:30PM	Loading…
Jan-31-24 04:30PM	DermTech Announces Additional Restructuring Actions to Focus on Revenue Growth and Streamline Operations (Business Wire)
Jan-18-24 08:05AM	DermTech Announces Positive Topline Results From a Study Evaluating the DermTech Melanoma Test (DMT) Across All Skin Types (Business Wire)
Jan-16-24 08:05AM	DermTech Simplifies the DermTech Melanoma Test (DMT) by Discontinuing the Optional TERT Add-on Assay (Business Wire) -8.45%
Jan-08-24 08:00AM	DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT) (Business Wire) +13.48%
Dec-14-23 04:05PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-08-23 03:34PM	DMTK STOCK NEWS: Shareholders With Large Losses Should Contact Robbins LLP for Information About Their Rights Against DermTech, Inc. (GlobeNewswire)
Nov-07-23 04:13PM	DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline (GlobeNewswire) +10.96%
Nov-03-23 09:35AM	DermTech, Inc. (NASDAQ:DMTK) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.71%
Nov-02-23 05:47PM	DermTech Inc (DMTK) Reports 10% Increase in Total Revenue for Q3 2023 (GuruFocus.com)
04:01PM	DermTech Reports Third-Quarter 2023 Financial Results (Business Wire)
09:32AM	Loading…
Oct-23-23 09:32AM	DMTK INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that DermTech, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -6.87%
Oct-18-23 03:55PM	DermTech, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; December 15, 2023 deadline (GlobeNewswire)
Oct-12-23 08:05AM	DermTech Announces Release Date for Third-Quarter 2023 Financial Results (Business Wire) -8.22%
Sep-21-23 04:05PM	DermTech Grants New CCO Mark Aguillard Inducement Award Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Sep-19-23 08:05AM	DermTech Announces Contracts With Highmark for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire)
Sep-13-23 05:55PM	Insider Sell: DermTech Inc CFO Kevin Sun Sells 9,616 Shares (GuruFocus.com)
Sep-11-23 08:05AM	DermTech Appoints Mark Aguillard as Chief Commercial Officer (Business Wire) +9.38%
Aug-31-23 09:40AM	Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Aug-25-23 08:05AM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-09-23 09:06AM	DermTech (NASDAQ:DMTK) Will Have To Spend Its Cash Wisely (Simply Wall St.)
Aug-03-23 05:35PM	DermTech, Inc. (DMTK) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	DermTech Reports Second-Quarter 2023 Financial Results (Business Wire)
Jul-19-23 08:00AM	DermTech Announces Favorable Coverage Policy With Blues Plan in Michigan for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire) +19.56%
Jul-17-23 08:00AM	DermTech Announces Release Date for Second-Quarter 2023 Financial Results (Business Wire) +5.38%
Jul-13-23 07:43AM	DermTech, Inc. (NASDAQ:DMTK) surges 21%; retail investors who own 59% shares profited along with institutions (Simply Wall St.)
08:00AM	Loading…
Jul-12-23 08:00AM	DermTech Adds Approximately 7 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire) +7.52%
Jun-28-23 04:30PM	DermTech Announces Restructuring to Prioritize Growth Opportunities and Streamline Operations (Business Wire)
Jun-20-23 05:25AM	If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position (Motley Fool) -5.43%
Jun-14-23 08:00AM	ECRI Completes Evaluation of the Pigmented Lesion Assay (PLA), the Foundational Assay for the DermTech Melanoma Test (DMT) (Business Wire) -5.33%
Jun-07-23 08:00AM	DermTech Announces Contract With Hawaii Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire)
Jun-02-23 04:05PM	DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
May-31-23 08:00AM	DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT) (Business Wire)
May-11-23 08:00AM	DermTech Announces Agreements With South Carolina Blues Plan and the United Mine Workers of America Health and Retirement Funds for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire) -11.83%
May-10-23 10:40AM	DermTech, Inc. (NASDAQ:DMTK) Analysts Just Slashed This Year's Revenue Estimates By 16% (Simply Wall St.) -5.07%
08:00AM	DermTech Grants New CEO Bret Christensen Inducement Award Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
May-09-23 08:00AM	DermTech Appoints Bret Christensen as New President and CEO (Business Wire) +10.84%
May-06-23 08:40AM	DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37% (Simply Wall St.)
May-04-23 05:45PM	DermTech, Inc. (DMTK) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +7.51%
04:01PM	DermTech Reports First-Quarter 2023 Financial Results (Business Wire)
May-01-23 04:30PM	New Survey Data Reveals Nearly 75% of Consumers Have Not Had a Full Skin Exam Within the Past 12 Months (Business Wire)
Apr-26-23 08:05AM	DermTech Announces Contract With New York Health Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire)
Apr-13-23 08:05AM	DermTech Announces Release Date for First-quarter 2023 Financial Results (Business Wire)
Apr-11-23 08:05AM	DermTech Announces Contract With North Carolina Blues Plan for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire) +18.21%
Apr-05-23 10:00AM	New Survey Finds Millennials and Gen Xers Not Following Safe Sun Habits, Increasing Risk of Nonmelanoma Skin Cancer (Business Wire) -6.17%
Apr-03-23 04:15PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-14-23 04:30PM	DermTech to Present Four New Posters and Demonstrate its Smart Stickers at the 2023 American Academy of Dermatology (AAD) Annual Meeting (Business Wire)
Mar-07-23 08:05AM	DermTech Adds Approximately 1.9 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire)
Mar-06-23 05:52AM	DermTech, Inc. (NASDAQ:DMTK) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.52%
Mar-03-23 08:05AM	DermTech to Present at March Investor Conferences (Business Wire) +17.37%
Mar-02-23 05:15PM	DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -7.77%
04:01PM	DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan (Business Wire)
Feb-12-23 09:53AM	Here's Why We're Watching DermTech's (NASDAQ:DMTK) Cash Burn Situation (Simply Wall St.)
Feb-10-23 08:30AM	DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results (Business Wire) -5.48%
Feb-09-23 08:30AM	DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration (Business Wire) +17.98%
Jan-27-23 08:30AM	DermTech Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Jan-23-23 08:30AM	DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire) +23.67%
Jan-18-23 05:55AM	This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run (Motley Fool) -25.47%
Jan-16-23 07:04AM	Institutions profited after DermTech, Inc.'s (NASDAQ:DMTK) market cap rose US$79m last week butindividual investors profited the most (Simply Wall St.)
Jan-10-23 08:30AM	DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE (Business Wire) +47.25%
Jan-05-23 08:30AM	DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT) (Business Wire) +8.54%
Dec-20-22 05:37AM	DermTech (NASDAQ:DMTK investor one-year losses grow to 89% as the stock sheds US$8.8m this past week (Simply Wall St.)
Dec-16-22 04:05PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-15-22 04:30PM	DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test (Business Wire)
Nov-09-22 05:48AM	DermTech Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.) +9.84%
Nov-06-22 07:06AM	DermTech, Inc. (NASDAQ:DMTK) Analysts Are Cutting Their Estimates: Here's What You Need To Know (Simply Wall St.)
Nov-03-22 05:55PM	DermTech, Inc. (DMTK) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	DermTech Reports Third-Quarter 2022 Financial Results (Business Wire)
Oct-13-22 04:05PM	DermTech Announces Release Date for Third-Quarter 2022 Financial Results (Business Wire)
Oct-10-22 04:30PM	DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress (Business Wire)
04:05PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-03-22 04:30PM	DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California (Business Wire)
Sep-16-22 04:30PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.21%
Sep-07-22 10:00AM	Will These Two Stocks Boom or Bust? (Motley Fool) +6.08%
Aug-08-22 05:45PM	DermTech, Inc. (DMTK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:01PM	DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook (Business Wire)
Aug-02-22 11:03AM	Is DermTech, Inc. (NASDAQ:DMTK) Popular Amongst Insiders? (Simply Wall St.)
Aug-01-22 10:01AM	Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline (Zacks)
Jul-28-22 04:05PM	DermTech Appoints Chief Compliance Officer and SVP of Research and Development (Business Wire)
Jul-26-22 04:05PM	DermTech Announces Release Date for Second-Quarter 2022 Financial Results (Business Wire)
Jul-18-22 04:05PM	DermTech Appoints Two New Board Members (Business Wire)
Jul-06-22 04:30PM	DermTech Joins PeDRA Corporate Council, Supporting Efforts to Address Pediatric Skin Diseases (Business Wire)
Jul-03-22 10:45AM	Investors one-year losses grow to 85% as the stock sheds US$29m this past week (Simply Wall St.)
Jun-20-22 05:09AM	Agiliti (AGTI) Stock Jumps 5.5%: Will It Continue to Soar? (Zacks)
Jun-14-22 04:05PM	DermTech to Present on Genomic Innovation in Dermatology at AHIP 2022 (Business Wire)
Jun-07-22 05:00PM	DermTech Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.71%
Jun-02-22 10:36AM	Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely? (Simply Wall St.) +8.55%
Jun-01-22 04:05PM	DermTech to Present at the William Blair Growth Stock Conference (Business Wire) -6.63%
May-24-22 04:30PM	DermTech Sponsors The Sun Bus to Bring Free Skin Cancer Screenings to More Than 50 Locations Across the U.S. (Business Wire)
May-18-22 04:30PM	DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatologys Annual Meeting (Business Wire) -8.77%
May-10-22 04:30PM	DermTech Reinforces Longstanding Mission to Help Reduce Melanoma Deaths, Aligning with the Biden Administrations Renewed Cancer Moonshot Program (Business Wire)
May-08-22 08:11PM	Time to Bottom Fish? 3 Strong Buy Stocks That Are Down Around 50% This Year (TipRanks)
May-04-22 04:30PM	DermTech Kicks Off Second Annual #Stickit2Melanoma Campaign, Raising Awareness for Melanoma and the Importance of Skin Exams (Business Wire)
May-03-22 05:15PM	DermTech, Inc. (DMTK) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	DermTech Reports First-Quarter 2022 Financial Results; Company Affirms Full-Year 2022 Outlook (Business Wire)
Apr-28-22 04:30PM	DermTech Announces Publication of New GvHD Clinical Research Conducted in Collaboration with Memorial Sloan Kettering Cancer Center (Business Wire)

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sun Kevin M	Chief Financial Officer	Dec 11 '23	Sale	1.45	447	648	277,499	Dec 11 08:02 PM
Ibarra Claudia	Chief Operating Officer	Dec 11 '23	Sale	1.45	331	480	193,547	Dec 11 08:02 PM
Ibarra Claudia	Chief Operating Officer	Dec 08 '23	Sale	1.41	2,607	3,676	193,878	Dec 11 08:02 PM
Sun Kevin M	Chief Financial Officer	Dec 07 '23	Sale	1.53	4,979	7,618	277,946	Dec 11 08:02 PM
Ibarra Claudia	Chief Operating Officer	Dec 07 '23	Sale	1.53	3,911	5,984	196,485	Dec 11 08:02 PM
Akhavan Ramin	General Counsel	Dec 07 '23	Sale	1.53	3,768	5,765	139,119	Dec 11 08:01 PM
Sun Kevin M	Chief Financial Officer	Sep 11 '23	Sale	1.89	436	824	282,925	Sep 12 08:07 PM
Ibarra Claudia	Chief Operating Officer	Sep 11 '23	Sale	1.89	322	609	200,396	Sep 12 08:06 PM
Sun Kevin M	Chief Financial Officer	Sep 08 '23	Sale	1.93	9,180	17,717	283,361	Sep 12 08:07 PM
Ibarra Claudia	Chief Operating Officer	Sep 08 '23	Sale	1.93	7,378	14,240	200,718	Sep 12 08:06 PM
Akhavan Ramin	General Counsel	Sep 08 '23	Sale	1.93	4,531	8,745	142,887	Sep 12 08:04 PM
Sun Kevin M	Chief Financial Officer	Jun 12 '23	Sale	2.85	437	1,245	290,041	Jun 14 08:16 PM
Wood Todd Michael	Chief Commercial Officer	Jun 12 '23	Sale	2.85	350	998	284,757	Jun 14 08:17 PM
Ibarra Claudia	Chief Operating Officer	Jun 12 '23	Sale	2.85	322	918	208,096	Jun 14 08:13 PM
Sun Kevin M	Chief Financial Officer	Jun 08 '23	Sale	2.61	2,828	7,381	290,478	Jun 09 06:47 PM
Ibarra Claudia	Chief Operating Officer	Jun 08 '23	Sale	2.61	2,371	6,188	208,418	Jun 09 06:47 PM
Wood Todd Michael	Chief Commercial Officer	Jun 07 '23	Sale	2.53	4,992	12,630	285,107	Jun 09 06:52 PM
Sun Kevin M	Chief Financial Officer	Jun 07 '23	Sale	2.53	4,988	12,620	293,306	Jun 09 06:47 PM
Ibarra Claudia	Chief Operating Officer	Jun 07 '23	Sale	2.53	3,916	9,907	210,789	Jun 09 06:47 PM
Akhavan Ramin	General Counsel	Jun 07 '23	Sale	2.53	3,776	9,553	147,418	Jun 09 06:46 PM

Open in Screener

RCKT

Rocket Pharmaceuticals Inc

May 03 • 04:00PM ET

23.47

Dollar change +0.70
Percentage change 3.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

RCKT Rocket Pharmaceuticals Inc daily Stock Chart

Held by: VTI IWM VXF VB IBB VBK IWO SCHA VTWO LABU

Index	RUT	P/E	-	EPS (ttm)	-2.94	Insider Own	7.21%	Shs Outstand	90.28M	Perf Week	6.78%
Market Cap	2.12B	Forward P/E	-	EPS next Y	-1.81	Insider Trans	-6.30%	Shs Float	83.98M	Perf Month	-6.04%
Income	-245.59M	PEG	-	EPS next Q	-0.67	Inst Own	96.55%	Short Float	13.10%	Perf Quarter	-17.79%
Sales	0.00M	P/S	-	EPS this Y	10.22%	Inst Trans	5.54%	Short Ratio	14.92	Perf Half Y	23.53%
Book/sh	5.46	P/B	4.30	EPS next Y	31.03%	ROA	-43.93%	Short Interest	11.00M	Perf Year	32.15%
Cash/sh	4.12	P/C	5.69	EPS next 5Y	41.70%	ROE	-50.01%	52W Range	14.89 - 32.53	Perf YTD	-21.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.09%	ROI	-47.70%	52W High	-27.84%	Beta	1.09
Dividend TTM	-	Quick Ratio	7.80	Sales past 5Y	0.00%	Gross Margin	-	52W Low	57.62%	ATR (14)	1.11
Dividend Ex-Date	-	Current Ratio	7.80	EPS Y/Y TTM	10.53%	Oper. Margin	0.00%	RSI (14)	46.12	Volatility	4.49% 4.35%
Employees	268	Debt/Eq	0.05	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.14	Target Price	49.33
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	30.17%	Payout	-	Rel Volume	0.85	Prev Close	22.77
Sales Surprise	-	EPS Surprise	17.79%	Sales Q/Q	-	Earnings	Feb 26 AMC	Avg Volume	737.79K	Price	23.47
SMA20	-0.29%	SMA50	-9.83%	SMA200	1.45%	Trades		Volume	630,424	Change	3.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy	$64
Feb-18-21	Initiated	Needham	Buy	$75
Dec-16-20	Initiated	UBS	Buy	$75
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy	$34
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy	$30
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy	$27
Feb-05-19	Initiated	Oppenheimer	Outperform	$39
Sep-13-18	Initiated	Ladenburg Thalmann	Buy	$30

Show Previous Ratings

Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
11:30AM	Loading…
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
11:17AM	Loading…
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily)
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)
Sep-18-23 07:30AM	Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully (Motley Fool)
Sep-15-23 11:00AM	Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week (Zacks)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks) +13.28%
04:34PM	Loading…
Sep-13-23 04:34PM	These Stocks Moved the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com) +38.85%
01:50PM	Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce (Investor's Business Daily)
01:36PM	These Stocks Are Moving the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com)
12:30PM	Stock Market Weighs In On Inflation Data; Vaccine Maker Leads The S&P 500 (Investor's Business Daily)
12:23PM	What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today? (Benzinga)
12:15PM	Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023 (AP Finance)
11:56AM	Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday (Motley Fool)
10:54AM	Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential Value Driver. (Barrons.com)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
12:01AM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
Sep-12-23 04:02PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease (Business Wire)
Sep-06-23 04:05PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-10-23 07:14AM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +6.25%
Jun-12-23 04:34PM	3 Small-Cap Stocks You Cant Ignore Now (InvestorPlace)
Jun-09-23 09:24AM	Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag (Zacks)
Jun-08-23 07:00AM	Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-31-23 07:00AM	Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
May-23-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) (Business Wire)
May-19-23 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-18-23 06:12AM	Heres Why Rocket Pharmaceuticals (RCKT) Stock Suffered in Q1 (Insider Monkey)
May-17-23 04:26PM	Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist (Yahoo Finance Video)
May-09-23 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-04-23 04:21PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +5.24%
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
May-03-23 04:01PM	Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference (Business Wire)
Apr-11-23 04:01PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Apr-04-23 04:01PM	Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage (Business Wire)
Mar-01-23 04:01PM	Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference (Business Wire) +5.41%
Feb-27-23 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (Business Wire)
Feb-09-23 04:01PM	Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
Feb-05-23 09:07AM	Even with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70k (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-23-23 10:15AM	Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:55AM	Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet (Zacks)
Jan-09-23 04:01PM	Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease (Business Wire)
Jan-06-23 09:55AM	Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade (Zacks)
Jan-03-23 04:01PM	Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-22 06:00AM	Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting (Business Wire) -13.90%
Dec-12-22 10:00AM	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire) +6.58%
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Dec-01-22 04:01PM	Rocket Pharmaceuticals Completes Acquisition of Renovacor (Business Wire)
Nov-21-22 08:00AM	Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-16-22 07:59AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (Simply Wall St.) -5.99%
Nov-03-22 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)
09:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses (Business Wire)
Oct-27-22 09:55AM	Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks)
Oct-14-22 06:35PM	Alkermes, Allakos, and Other Stocks See Action From Activist Investors (Barrons.com)
Oct-12-22 06:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-11-22 09:55AM	Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect? (Zacks)
Oct-10-22 08:00AM	Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa (Business Wire)
Oct-03-22 11:21PM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
04:42PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Sep-30-22 06:00AM	Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 (Business Wire) +13.68%
Sep-27-22 08:00AM	Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference (Business Wire) +7.41%
Sep-20-22 05:07PM	Cambridge biotech acquired for $53M following move from Philadelphia (American City Business Journals)
11:14AM	Why Is Renovacor (RCOR) Stock Up 18% Today? (InvestorPlace)
10:06AM	Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases (Benzinga)
06:00AM	Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy (Business Wire)
Sep-16-22 08:00AM	Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022 (Business Wire) -10.21%
Sep-06-22 08:00AM	Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference (Business Wire) -5.66%
Aug-15-22 09:13AM	15 Small Company Stocks You Should Own Now for the Next Decade (Insider Monkey)
Aug-11-22 02:11PM	Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade (Investor's Business Daily)
Aug-08-22 04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)
Jul-27-22 07:00AM	Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities (Business Wire)
Jul-20-22 06:33AM	A Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) insider increased their holdings by 2.4% last year (Simply Wall St.)

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Militello John	See Remarks	Apr 22 '24	Sale	22.87	833	19,051	54,406	Apr 24 04:06 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Option Exercise	4.34	29,624	128,627	124,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Sale	24.05	10,000	240,520	114,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Option Exercise	4.34	70,000	303,940	165,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Sale	24.36	70,000	1,705,265	95,160	Apr 16 05:45 PM
White Mark Andrew	See Remarks	Apr 08 '24	Sale	24.64	12,532	308,763	75,226	Apr 10 08:39 PM
Makker Gotham	Director	Mar 21 '24	Sale	28.43	274,000	7,790,943	365,912	Mar 25 08:58 PM
Militello John	See Remarks	Mar 21 '24	Sale	28.10	2,490	69,979	55,239	Mar 25 08:54 PM
Militello John	See Remarks	Feb 29 '24	Option Exercise	12.55	10,000	125,500	31,517	Mar 04 06:54 PM
Militello John	See Remarks	Feb 29 '24	Sale	29.84	10,000	298,450	21,517	Mar 04 06:54 PM
Wilson Martin	General Counsel	Feb 29 '24	Sale	29.33	4,100	120,257	18,680	Mar 04 06:48 PM
Shah Gaurav	CEO	Feb 16 '24	Sale	29.84	20,272	604,876	554,762	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 16 '24	Sale	29.84	7,132	212,805	238,346	Feb 21 08:54 PM
Wilson Martin	General Counsel	Feb 16 '24	Sale	29.84	3,576	106,701	6,136	Feb 21 08:54 PM
Militello John	See Remarks	Feb 16 '24	Sale	29.84	3,238	96,615	13,195	Feb 21 08:54 PM
Militello John	See Remarks	Feb 14 '24	Option Exercise	0.00	6,274	0	16,433	Feb 16 04:05 PM
Patel Kinnari	See Remarks	Feb 14 '24	Option Exercise	0.00	26,189	0	245,478	Feb 16 04:05 PM
Militello John	See Remarks	Jan 22 '24	Sale	27.20	638	17,356	10,159	Jan 23 04:22 PM
Militello John	See Remarks	Jan 18 '24	Option Exercise	0.00	1,586	0	10,797	Jan 22 04:05 PM
Makker Gotham	Director	Nov 15 '23	Sale	22.53	20,000	450,646	1,296,497	Nov 16 07:24 PM
Militello John	See Remarks	Nov 14 '23	Option Exercise	0.00	725	0	9,485	Nov 16 06:58 PM
Patel Kinnari	See Remarks	Nov 14 '23	Option Exercise	0.00	3,989	0	220,437	Nov 16 07:17 PM
Militello John	See Remarks	Oct 20 '23	Sale	17.06	564	9,623	8,760	Oct 25 09:38 AM
Patel Kinnari	See Remarks	Oct 05 '23	Option Exercise	0.00	3,333	0	101,594	Oct 10 04:11 PM
Makker Gotham	Director	Sep 29 '23	Sale	21.14	4,677	98,864	1,316,497	Oct 02 09:02 PM
Makker Gotham	Director	Sep 28 '23	Sale	21.03	10,312	216,880	1,321,174	Oct 02 09:02 PM
Shah Gaurav	CEO	Aug 17 '23	Sale	15.47	4,767	73,750	524,854	Aug 21 04:05 PM
Patel Kinnari	See Remarks	Aug 17 '23	Sale	15.47	1,534	23,733	216,448	Aug 21 04:05 PM
Militello John	See Remarks	Aug 17 '23	Sale	15.47	284	4,394	5,570	Aug 21 04:05 PM
Patel Kinnari	See Remarks	Aug 14 '23	Option Exercise	0.00	3,989	0	217,982	Aug 15 04:16 PM
Militello John	See Remarks	Aug 14 '23	Option Exercise	0.00	725	0	7,854	Aug 15 04:17 PM
Shah Gaurav	CEO	Aug 14 '23	Option Exercise	0.00	7,979	0	529,621	Aug 15 04:06 PM
Militello John	See Remarks	Jul 20 '23	Sale	19.03	573	10,906	7,129	Jul 24 04:05 PM
Militello John	See Remarks	Jul 18 '23	Option Exercise	0.00	1,586	0	7,702	Jul 20 04:05 PM
Shah Gaurav	CEO	May 17 '23	Sale	21.38	4,122	88,108	521,642	May 19 04:05 PM
Patel Kinnari	See Remarks	May 17 '23	Sale	21.38	1,330	28,429	213,993	May 19 04:05 PM
Militello John	See Remarks	May 17 '23	Sale	21.38	245	5,237	6,116	May 19 04:05 PM
Militello John	See Remarks	May 14 '23	Option Exercise	0.00	725	0	6,361	May 16 08:01 PM
Shah Gaurav	CEO	May 14 '23	Option Exercise	0.00	7,979	0	525,764	May 16 08:04 PM
Patel Kinnari	See Remarks	May 14 '23	Option Exercise	0.00	3,989	0	215,323	May 16 07:57 PM

Open in Screener

LABP

Landos Biopharma Inc

May 03 • 04:00PM ET

22.24

Dollar change -0.01
Percentage change -0.07	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

LABP Landos Biopharma Inc daily Stock Chart

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-3.49	Insider Own	9.92%	Shs Outstand	3.12M	Perf Week	-0.34%
Market Cap	69.37M	Forward P/E	-	EPS next Y	-1.69	Insider Trans	0.00%	Shs Float	2.81M	Perf Month	3.42%
Income	-21.93M	PEG	-	EPS next Q	-1.00	Inst Own	50.54%	Short Float	0.03%	Perf Quarter	321.12%
Sales	0.00M	P/S	-	EPS this Y	37.43%	Inst Trans	-32.02%	Short Ratio	0.03	Perf Half Y	455.88%
Book/sh	10.20	P/B	2.18	EPS next Y	23.06%	ROA	-52.67%	Short Interest	0.00M	Perf Year	666.72%
Cash/sh	12.04	P/C	1.85	EPS next 5Y	-	ROE	-61.86%	52W Range	2.50 - 22.84	Perf YTD	507.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.32%	ROI	-69.00%	52W High	-2.65%	Beta	0.14
Dividend TTM	-	Quick Ratio	6.09	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	789.40%	ATR (14)	0.44
Dividend Ex-Date	-	Current Ratio	6.09	EPS Y/Y TTM	64.21%	Oper. Margin	0.00%	RSI (14)	85.04	Volatility	1.43% 1.20%
Employees	19	Debt/Eq	0.00	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	2.33	Target Price	9.56
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	24.16%	Payout	-	Rel Volume	0.15	Prev Close	22.25
Sales Surprise	-	EPS Surprise	-8.20%	Sales Q/Q	-	Earnings	Mar 21 BMO	Avg Volume	25.30K	Price	22.24
SMA20	1.55%	SMA50	47.36%	SMA200	223.19%	Trades		Volume	3,863	Change	-0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-12-22	Downgrade	Jefferies	Buy → Hold	$30 → $1.40
Nov-16-21	Downgrade	SVB Leerink	Outperform → Mkt Perform	$20 → $16
Oct-20-21	Initiated	Craig Hallum	Buy	$45
Oct-19-21	Initiated	H.C. Wainwright	Buy	$50
Mar-01-21	Initiated	SVB Leerink	Outperform	$20
Mar-01-21	Initiated	Raymond James	Outperform	$33
Mar-01-21	Initiated	JP Morgan	Neutral	$17
Mar-01-21	Initiated	Jefferies	Buy	$32

Apr-30-24 08:38AM	AbbVie Inc. (NYSE:ABBV) Q1 2024 Earnings Call Transcript (Insider Monkey)
Mar-25-24 01:27PM	Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? (Benzinga) +173.31%
12:17PM	Why Is Landos Biopharma (LABP) Stock Up 168% Today? (InvestorPlace)
09:25AM	AbbVie grabs a wrench to add immunology-focused Landos Biopharma for $137.5M (FierceBiotech.com)
08:31AM	AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases (PR Newswire)
08:05AM	Loading…
08:05AM	AbbVie to buy immune drug developer Landos (BioPharma Dive)
Mar-21-24 01:52PM	LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023 (InvestorPlace) +9.73%
08:00AM	Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results (GlobeNewswire)
Jan-08-24 08:00AM	Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn's and Colitis Organisation (GlobeNewswire)
Nov-21-23 08:00AM	Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn's and Colitis (GlobeNewswire) +7.42%
Nov-09-23 08:00AM	Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results (GlobeNewswire) -7.49%
Oct-23-23 08:00AM	Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting (GlobeNewswire)
Sep-19-23 08:00AM	Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress (GlobeNewswire)
Sep-14-23 08:00AM	Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells (GlobeNewswire)
Aug-09-23 08:00AM	Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results (GlobeNewswire)
04:15PM	Loading…
May-31-23 04:15PM	Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference (GlobeNewswire) -8.61%
May-30-23 04:15PM	Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D. (GlobeNewswire)
May-25-23 04:05PM	Landos Biopharma Announces 1-for-10 Reverse Stock Split (GlobeNewswire) -6.03%
May-12-23 08:50AM	UPDATE -- Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results (GlobeNewswire)
08:00AM	Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results (GlobeNewswire)
Mar-23-23 08:00AM	Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2022 Results (GlobeNewswire) -12.26%
Feb-28-23 05:00PM	Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos Founder (GlobeNewswire)
Jan-11-23 07:00AM	Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohns and Colitis Organization (GlobeNewswire) +11.75%
Jan-05-23 07:05AM	Landos Biopharma Provides Comprehensive Update on Clinical Development Plans (GlobeNewswire)
07:00AM	Landos Biopharma Announces $16.7 Million Private Placement Financing (GlobeNewswire)
Nov-10-22 08:00AM	Landos Biopharma Reports Third Quarter 2022 Results and Provides Business Update (GlobeNewswire) +17.39%
Oct-15-22 09:36AM	We're A Little Worried About Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate (Simply Wall St.)
Sep-06-22 07:00AM	Landos Biopharma Announces Appointment of Fabio Cataldi, MD, as Chief Medical Officer (GlobeNewswire)
Aug-12-22 06:37PM	Raymond James Is Bearish On This Inflammatory Bowel Disease Player On Upcoming 'Pipeline Reset' (Benzinga)
Aug-11-22 08:30AM	Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update (GlobeNewswire) -12.20%
08:00AM	Loading…
Aug-03-22 08:00AM	Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1b Trial (GlobeNewswire) +17.03%
Jun-21-22 08:00AM	Landos Names Gregory Oakes President and Chief Executive Officer (GlobeNewswire)
May-13-22 08:28AM	The Zacks Analyst Blog Highlights Angion Biomedica, Applied Therapeutics, Bolt Biotherapeutics, Ikena Oncology, and Landos Biopharma (Zacks)
May-12-22 04:05PM	Landos Biopharma Reports First Quarter 2022 Results and Provides Business Update (GlobeNewswire) +5.72%
May-11-22 07:32AM	5 Biotech Stocks Set to Outpace Q1 Earnings Estimates (Zacks) -8.11%
May-08-22 09:00AM	We're Keeping An Eye On Landos Biopharma's (NASDAQ:LABP) Cash Burn Rate (Simply Wall St.)
Mar-24-22 04:45PM	Landos Biopharma Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update (GlobeNewswire)
Mar-10-22 08:00AM	Landos Biopharma Appoints Roger Adsett to its Board of Directors (GlobeNewswire) -5.88%
Feb-04-22 07:23AM	What Percentage Of Landos Biopharma, Inc. (NASDAQ:LABP) Shares Do Insiders Own? (Simply Wall St.) -8.42%
Nov-17-21 08:33AM	Here's Why We're Not At All Concerned With Landos Biopharma's (NASDAQ:LABP) Cash Burn Situation (Simply Wall St.)
Nov-15-21 07:30AM	Landos Biopharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update (GlobeNewswire) -6.48%
Nov-11-21 04:05PM	Landos Biopharma to Host Corporate Update Call (GlobeNewswire)
Nov-10-21 08:32AM	Should You Buy Landos Biopharma (LABP) Ahead of Earnings? (Zacks)
Nov-08-21 08:10AM	Landos Biopharma Announces Leadership Transition (GlobeNewswire)
Nov-02-21 08:28AM	Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis (GlobeNewswire)
Oct-28-21 07:00AM	Landos Biopharma Announces First Subject Dosed in a Phase 1 Study of LABP-104 for Systemic Lupus Erythematosus (GlobeNewswire)
Oct-15-21 08:49AM	10 Best Biotech Stocks to Buy According to Joseph Edelmans Perceptive Advisors (Insider Monkey)
Oct-11-21 07:00AM	Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus (GlobeNewswire)
Oct-06-21 07:00AM	Landos Biopharma Announces Publication in Scientific Reports of Novel Preclinical Findings Demonstrating Omilancors Therapeutic Potential in Models of Psoriasis and Further Validating the LANCL2 Mechanism (GlobeNewswire)
Sep-27-21 07:00AM	Landos Biopharma to Participate in Truist Securities CEO Fireside Chat Series (Virtual) (GlobeNewswire)
Sep-20-21 07:00AM	Landos Biopharma to Collaborate on a Phase 2 Study of Omilancor in Crohns Disease with the Icahn School of Medicine at Mount Sinai (GlobeNewswire)
Sep-15-21 07:00AM	Landos Biopharma to Present Results of LABP-104 in Lupus at the American College of Rheumatology Convergence 2021 (GlobeNewswire) +11.21%
Sep-01-21 07:00AM	Landos Biopharma to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-26-21 07:00AM	Landos Biopharma Announces Research Collaboration into the NLRX1 Pathway in Multiple Sclerosis with Johns Hopkins University School of Medicine (GlobeNewswire)
Aug-19-21 03:03PM	Here's What Landos Biopharma, Inc.'s (NASDAQ:LABP) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Aug-05-21 07:00AM	Landos Biopharma to Participate in Upcoming Investor Events (GlobeNewswire) +8.89%
Jul-22-21 07:00AM	Landos Biopharmas Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021 (GlobeNewswire)
Jun-14-21 05:08PM	Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference (GlobeNewswire)
07:00AM	Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients (GlobeNewswire)
May-25-21 07:00AM	Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference (GlobeNewswire)
May-19-21 07:00AM	Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors (GlobeNewswire)
May-17-21 09:29AM	Landos Biopharma, LianBio Ink Licensing Pact For Omilancor & NX-13 in Greater China (Benzinga)
07:15AM	Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets (GlobeNewswire)
May-06-21 04:01PM	Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohns Disease (GlobeNewswire)
May-04-21 08:51AM	Is Landos Biopharma (NASDAQ:LABP) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-29-21 07:00AM	Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis (GlobeNewswire)
Apr-26-21 11:56AM	Raymond James: These 3 Stocks Have Over 100% Upside on the Horizon (TipRanks) +16.21%
07:00AM	Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting (GlobeNewswire)
Apr-13-21 07:00AM	Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors (GlobeNewswire)
Apr-06-21 09:53AM	Landos Biopharma Stock Is Trading Higher On Initiating Early-Stage Study With Omilancor For Esophagus Inflammation (Benzinga) +7.99%
07:00AM	Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis (GlobeNewswire)
Mar-04-21 07:00AM	Landos Biopharma Announces Positive Results from a Phase 1 Study of NX-13 in Healthy Volunteers (GlobeNewswire) -15.35%
Feb-26-21 06:26PM	Bausch Health and Landos Biopharma See Activist Action (Barrons.com)
Feb-23-21 04:00PM	Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference (GlobeNewswire) -6.46%
Feb-05-21 05:26PM	The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market (Barrons.com) -7.92%
Feb-04-21 05:56PM	A Busy Day for Biotech IPOs (Barrons.com)
Feb-03-21 08:13PM	Landos Biopharma Announces Pricing of Initial Public Offering (GlobeNewswire)

Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.

Open in Screener

MIST

Milestone Pharmaceuticals Inc

May 03 • 04:00PM ET

1.69

Dollar change +0.05
Percentage change 3.05	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

MIST Milestone Pharmaceuticals Inc daily Stock Chart

Held by: GWX

Index	-	P/E	-	EPS (ttm)	-1.48	Insider Own	3.20%	Shs Outstand	53.15M	Perf Week	9.74%
Market Cap	89.82M	Forward P/E	-	EPS next Y	-1.54	Insider Trans	0.00%	Shs Float	51.45M	Perf Month	-3.43%
Income	-59.69M	PEG	-	EPS next Q	-0.26	Inst Own	31.83%	Short Float	0.84%	Perf Quarter	3.68%
Sales	1.00M	P/S	89.82	EPS this Y	17.27%	Inst Trans	4.34%	Short Ratio	1.31	Perf Half Y	-39.64%
Book/sh	0.50	P/B	3.37	EPS next Y	-34.35%	ROA	-79.73%	Short Interest	0.43M	Perf Year	-53.06%
Cash/sh	1.24	P/C	1.36	EPS next 5Y	-	ROE	-143.61%	52W Range	1.33 - 4.49	Perf YTD	1.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-7.22%	ROI	-87.77%	52W High	-62.36%	Beta	1.77
Dividend TTM	-	Quick Ratio	10.11	Sales past 5Y	-29.33%	Gross Margin	40.20%	52W Low	27.07%	ATR (14)	0.12
Dividend Ex-Date	-	Current Ratio	10.11	EPS Y/Y TTM	-7.56%	Oper. Margin	-6141.00%	RSI (14)	52.38	Volatility	6.78% 7.08%
Employees	47	Debt/Eq	3.09	Sales Y/Y TTM	-80.00%	Profit Margin	-5968.50%	Recom	1.50	Target Price	10.50
Option/Short	Yes / Yes	LT Debt/Eq	3.05	EPS Q/Q	-31.98%	Payout	-	Rel Volume	0.26	Prev Close	1.64
Sales Surprise	-	EPS Surprise	-2.40%	Sales Q/Q	-100.00%	Earnings	Mar 21 BMO	Avg Volume	330.14K	Price	1.69
SMA20	0.93%	SMA50	1.22%	SMA200	-27.90%	Trades		Volume	85,566	Change	3.05%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-20-23	Downgrade	Jefferies	Buy → Hold	$8 → $4
Apr-22-22	Upgrade	Piper Sandler	Neutral → Overweight	$8 → $10
Mar-05-21	Initiated	H.C. Wainwright	Buy	$20
Jul-29-20	Upgrade	Oppenheimer	Perform → Outperform	$18
Jul-24-20	Upgrade	Jefferies	Hold → Buy
Mar-25-20	Downgrade	Jefferies	Buy → Hold	$28 → $3
Mar-24-20	Downgrade	Piper Sandler	Overweight → Neutral	$26.50 → $3
Mar-24-20	Downgrade	Oppenheimer	Outperform → Perform
Jun-04-19	Initiated	Oppenheimer	Outperform	$32
Jun-03-19	Initiated	Piper Jaffray	Overweight	$26.50
Jun-03-19	Initiated	Jefferies	Buy	$28
Jun-03-19	Initiated	Cowen	Outperform	$32

Show Previous Ratings

May-02-24 08:00AM	Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024 (GlobeNewswire)
Apr-17-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium (GlobeNewswire)
Apr-08-24 11:36AM	Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference (GlobeNewswire)
Apr-01-24 08:00AM	Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences (GlobeNewswire)
07:00AM	Loading…
Mar-28-24 07:00AM	Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia (GlobeNewswire)
Mar-21-24 01:53PM	MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
07:14AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update (GlobeNewswire)
Feb-29-24 04:01PM	Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference (GlobeNewswire) -21.13%
07:00AM	Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-28-24 04:37PM	Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
Feb-26-24 07:00AM	Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT (GlobeNewswire) +24.12%
Jan-18-24 01:23PM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations: Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire)
Jan-16-24 09:35AM	Down -43.64% in 4 Weeks, Here's Why Milestone Pharmaceuticals (MIST) Looks Ripe for a Turnaround (Zacks)
Dec-27-23 11:11AM	Milestone Pharma (MIST) Down on Regulatory Update for Etripamil (Zacks) -5.53%
10:55AM	Loading…
Dec-26-23 10:55AM	Milestone Pharmaceuticals Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm (GlobeNewswire) -30.90%
07:00AM	Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT (GlobeNewswire)
Nov-21-23 07:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare Conference (PR Newswire) +13.16%
Nov-13-23 07:02AM	Milestone Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -19.59%
06:57AM	Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate Updates (PR Newswire)
Nov-11-23 10:00AM	Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023 (PR Newswire)
Nov-07-23 07:00AM	Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVR (PR Newswire)
Oct-24-23 07:00AM	Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for Etripamil (PR Newswire)
Oct-06-23 07:00AM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Sep-27-23 07:00AM	Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023 (PR Newswire)
Sep-05-23 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference (PR Newswire)
Aug-10-23 07:56AM	Milestone Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) +5.77%
07:35AM	Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Aug-08-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally All the Way to $10 (or More) (TipRanks) +17.63%
Jun-20-23 07:00AM	Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The Lancet (PR Newswire)
09:40AM	Loading…
Jun-10-23 09:40AM	Individual investors account for 48% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 38% (Simply Wall St.)
Jun-01-23 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference (PR Newswire) -6.09%
May-22-23 07:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular Rate (PR Newswire)
May-11-23 07:31AM	Milestone Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +8.97%
07:16AM	Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
May-08-23 07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular Rate (PR Newswire) +9.19%
May-01-23 06:02AM	Lorenz Muller Is The Chief Commercial Officer of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) And They Just Picked Up 23% More Shares (Simply Wall St.)
Apr-21-23 09:23AM	Milestone Pharmaceuticals' (NASDAQ:MIST) investors will be pleased with their decent 75% return over the last three years (Simply Wall St.)
Apr-12-23 07:00AM	Milestone Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-31-23 10:39AM	Despite recent gains, Milestone Pharmaceuticals Inc. (NASDAQ:MIST) insiders are still down US$91k after purchasing last year (Simply Wall St.)
Mar-29-23 09:17AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Mar-28-23 07:00AM	Milestone Pharmaceuticals Announces $125 Million Strategic Financing with RTW Investments to Support the Advancement of Etripamil for PSVT (PR Newswire) +10.83%
Mar-06-23 07:00AM	Milestone Pharmaceuticals Progresses Clinical and Regulatory Activities for Etripamil in Patients with Paroxysmal Supraventricular Tachycardia (PR Newswire) +12.23%
Feb-28-23 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Jan-16-23 12:00PM	Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why (Zacks)
Jan-01-23 08:33AM	Milestone Pharmaceuticals Inc. (NASDAQ:MIST) is definitely on the radar of institutional investors who own 33% of the company (Simply Wall St.)
Dec-13-22 09:35AM	Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 14.5% in 4 Weeks (Zacks)
Dec-02-22 02:11PM	Will Milestone Pharmaceuticals (NASDAQ:MIST) Spend Its Cash Wisely? (Simply Wall St.)
Nov-29-22 07:00AM	Milestone Pharmaceuticals to Host Virtual Commercial Deep-Dive Event on Etripamil for PSVT (PR Newswire)
Nov-22-22 07:00AM	Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference (PR Newswire)
Nov-12-22 07:47AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 74% over the last three years (Simply Wall St.)
Nov-10-22 07:21AM	Milestone Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +9.54%
Nov-07-22 12:13PM	Milestone Pharmaceuticals Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022 (PR Newswire) -10.32%
Oct-25-22 07:00AM	Milestone Pharmaceuticals Announces Late-Breaking Presentation of Data from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia at the American Heart Association Scientific Sessions 2022 (PR Newswire) +8.28%
Oct-22-22 08:21AM	Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) recent US$101m market cap decline means a loss of US$6.2k for insiders who bought this year (Simply Wall St.)
08:05AM	Independent Non-Executive Director Michael Tomsicek Just Bought A Handful Of Shares In Milestone Pharmaceuticals Inc. (NASDAQ:MIST) (Simply Wall St.)
Oct-20-22 09:35AM	Here's Why Milestone Pharmaceuticals (MIST) is Poised for a Turnaround After Losing 42.9% in 4 Weeks (Zacks) +5.44%
Oct-18-22 06:30PM	Milestone's (MIST) Tachycardia Study Data Fail to Impress Investors (Zacks) -9.92%
Oct-17-22 09:14AM	Milestone's stock jumps 25% on positive data for tachycardia treatment (MarketWatch) -21.67%
09:12AM	Milestone Pharma Stock Surges After Successful Trial For Abnormal Heart Rhythm Candidate (Benzinga)
06:00AM	Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia (PR Newswire)
Sep-11-22 03:13PM	Oppenheimer Says Biotech Stocks Look a Bit Brighter Right Now; Here Are 2 Names to Consider (TipRanks)
Sep-06-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference (PR Newswire)
Aug-10-22 04:15PM	Milestone Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Jul-24-22 10:28AM	What Type Of Shareholders Own The Most Number of Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares? (Simply Wall St.)
Jun-02-22 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Healthcare Conference (PR Newswire)
May-27-22 05:03PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +6.33%
May-23-22 06:23AM	We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth (Simply Wall St.)
May-17-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference (PR Newswire)
May-12-22 07:15AM	Milestone Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical and Corporate Update (PR Newswire) -7.40%
Apr-30-22 09:00AM	Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT (PR Newswire)
Apr-15-22 04:41PM	Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
10:20AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have made a respectable return of 36% over the past year (Simply Wall St.)
Apr-14-22 07:00AM	Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of PSVT (PR Newswire)
Mar-24-22 07:20AM	Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +9.28%
Mar-01-22 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Feb-16-22 07:00AM	Milestone Pharmaceuticals Announces Appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer (PR Newswire) -5.41%
Feb-14-22 01:03PM	Could The Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Ownership Structure Tell Us Something Useful? (Simply Wall St.)
Jan-04-22 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference (PR Newswire)
Dec-14-21 07:56AM	Milestone Pharmaceuticals (NASDAQ:MIST) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Nov-15-21 07:00AM	Milestone Pharmaceuticals Announces Presentation of Heart Rate Analysis of NODE-301 Trial of Etripamil in Patients with PSVT (PR Newswire) +13.93%
Nov-12-21 07:20AM	Milestone Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Clinical and Corporate Update (PR Newswire) +8.93%
Nov-11-21 07:00AM	Milestone Pharmaceuticals to Present at Upcoming Investor Conferences (PR Newswire)
Oct-15-21 09:31AM	Investors in Milestone Pharmaceuticals (NASDAQ:MIST) have unfortunately lost 18% over the last year (Simply Wall St.)
Sep-22-21 07:00AM	Milestone Pharmaceuticals to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference (PR Newswire)
Sep-07-21 07:00AM	Milestone Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire) -5.99%
Aug-16-21 10:58AM	What Kind Of Shareholders Own Milestone Pharmaceuticals Inc. (NASDAQ:MIST)? (Simply Wall St.)
Aug-11-21 04:18PM	Milestone Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Clinical and Corporate Update (PR Newswire)
Aug-03-21 09:01AM	10 Stocks to Buy According to Neil Shahrestanis Ikarian Capital (Insider Monkey) -6.56%
May-26-21 07:00AM	Milestone Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (PR Newswire)
May-17-21 01:22PM	Milestone Pharma-Ji Xing Pharma Ink $127M Etripamil Development Agreement For China (Benzinga)
07:02AM	Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21 (PR Newswire)
07:01AM	Milestone Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical, Regulatory, and Corporate Update (PR Newswire)

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

DMTK

DermTech Inc

RCKT

Rocket Pharmaceuticals Inc

LABP

Landos Biopharma Inc

MIST

Milestone Pharmaceuticals Inc

Upgrade your FINVIZ experience